A Phase 1/2a, Open-label, Multiple-Cohort, Dose-escalation Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 in Subjects with Neovascular (wet) Age-Related Macular Degeneration (nAMD).